(Q37371310)

20 August 2017

Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics (English)

1 reference

20 August 2017

1 reference

1 reference

10

H Watts

1 reference

20 August 2017

E V Capparelli

1

1 reference

20 August 2017

F Aweeka

2

1 reference

20 August 2017

J Hitti

3

1 reference

20 August 2017

A Stek

4

1 reference

20 August 2017

C Hu

5

1 reference

20 August 2017

S K Burchett

6

1 reference

20 August 2017

B Best

7

1 reference

20 August 2017

E Smith

8

1 reference

20 August 2017

J S Read

9

1 reference

20 August 2017

S Nachman

11

1 reference

20 August 2017

E M Thorpe

12

1 reference

20 August 2017

S A Spector

13

1 reference

20 August 2017

E Jimenez

14

1 reference

20 August 2017

W T Shearer

15

1 reference

20 August 2017

M Foca

16

1 reference

20 August 2017

M Mirochnick

17

1 reference

20 August 2017

PACTG 1026S Study Team

18

1 reference

20 August 2017

PACTG P1022 Study Team

19

1 reference

20 August 2017

1 April 2008

1 reference

20 August 2017

1 reference

20 August 2017

9

1 reference

20 August 2017

4

1 reference

20 August 2017

214-220

1 reference

Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2755564

Myelomeningocele in an infant with intrauterine exposure to efavirenz

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2755564

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2755564

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2755564

Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2755564

Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.

26 June 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00553.X

Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00553.X

Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00553.X

Reduced lopinavir exposure during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00553.X

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00553.X

Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00553.X

Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00553.X

Increased expression of MDR1 mRNAs and P-glycoprotein in placentas from HIV-1 infected women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00553.X

Transplacental passage of protease inhibitors at delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2008.00553.X

Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2755564

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2755564

Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2755564

Disposition and biotransformation of the antiretroviral drug nevirapine in humans.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2755564

Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450

2 September 2018

1 reference

12 December 2020

Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States (revised November 3, 2000).

1 reference

12 December 2020

Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy

1 reference

12 December 2020

Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery

1 reference

12 December 2020

10.1111/J.1468-1293.2008.00553.X

Identifiers

DOI

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

18366444

1 reference